Standardizing the slurry: International Dysphagia Diet Standardization Initiative testing of budesonide formulations for eosinophilic esophagitis.
Syverson Erin P EP, Hait Elizabeth E, IDDSI EoE Formulation Study Group
Teva Pharmaceutical Industries Ltd. · NR3C1 · 小分子
budesonide 是一种小分子,由Teva Pharmaceutical Industries Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。
| 商品名 | Xavin, Pulairmax, Aerosial |
| 公司 | Teva Pharmaceutical Industries Ltd. |
| 药物类别 | 小分子 |
| 分子靶点 | NR3C1 |
| 给药途径 | Inhaled |
| 状态 | Approved |
budesonide 作用于 1 个分子靶点:
| NR3C1 | nuclear receptor subfamily 3 group C member 1 (GR, GCCR) |
budesonide 针对 1 个适应症,涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Respiratory, thoracic and mediastinal disorders | Asthma | ✓ Approved |
Syverson Erin P EP, Hait Elizabeth E, IDDSI EoE Formulation Study Group
Braun Gerald S GS, Seikrit Claudia C
Targeted-release budesonide (Nefecon) is the first gut-kidney axis-directed therapy for high-risk immunoglobulin A nephropathy (IgAN) and relies on intact hepatic first-pass metabolism to limit systemic exposure. We report a 63-year-old man who developed acute portal vein thrombosis within 3 days of treatment initiation. Imaging demonstrated near-complete thrombosis of the portal venous system. Subsequent evaluation revealed previously unrecognized chronic liver disease, including hereditary hemochromatosis, alcohol use, and early hepatocellular carcinoma without vascular invasion. In conjunction with three previously reported cases of splanchnic vein thrombosis in patients receiving budesonide to treat advanced autoimmune hepatobiliary disease and published pharmacokinetic data, this observation suggests that hepatic dysfunction and disease may lower the thrombotic threshold for budesonide. These findings support careful assessment of hepatic function when initiating targeted-release budesonide in IgAN.
Chakravorty Aditya A, Chauhan Sanshriti S, Gulati Sanjeev S, Sabhikhi Abha A
Alas-Pineda César C, Ferrer Gustavo G, Pavón-Varela Dennis J DJ, Gaitán-Zambrano Kristhel K et al.
Background/Objectives: Pregnancy-recognized obstructive sleep apnea (POSA) is an operational construct, not a validated biological phenotype, and remains underrecognized in prenatal care. This review synthesizes evidence on POSA-related outcomes, evaluates gestational rhinitis as a candidate contributor to upper-airway vulnerability, and distinguishes pregnancy safety from demonstrated efficacy for OSA-related endpoints. Methods: This structured narrative review, informed by SANRA criteria, used a structured PubMed search (7 March 2026) with targeted supplementary searches through 9 October 2026, across six predefined domains. Results: Pregnancy-recognized OSA is associated in observational studies with hypertensive disorders, preterm birth, impaired fetal growth (in small pregnancy-specific studies), and severe maternal morbidity; residual confounding by obesity precludes causal inference. In a 2024 meta-analysis of randomized and observational studies (n = 809), continuous positive airway pressure (CPAP) was associated with lower risks of gestational hypertension (RR, 0.65; 95% CI, 0.47-0.89) and preeclampsia (RR, 0.70; 95% CI, 0.50-0.98). Although secondary endpoints in individual trials suggested benefit, the pooled preeclampsia effect was fragile in sensitivity and subgroup analyses. Gestational rhinitis affects approximately one in five pregnant women and is a plausible but untested contributor to pregnancy-recognized OSA. Saline irrigation, budesonide (mainly inhaled-exposure data), and chlorpheniramine have gestational safety data, but the only randomized trial of an intranasal corticosteroid in gestational rhinitis was null, and we identified no study of OSA endpoints. Conclusions: Given the largely observational evidence, objective testing and individualized treatment may be considered in high-risk patients, pending adequately powered trials. CPAP is the standard treatment for objectively confirmed OSA.
Pochesci Saverio S, Scarallo Luca L, Gianolio Laura L, Russell Richard K RK
While current paediatric management increasingly favours early intensive treatment for children and adolescents with Crohn's disease (CD) at high risk of disease progression, a smaller subset of patients presents with a potentially 'low-risk' disease phenotype. Identifying these children is clinically challenging, as overtreatment may expose them to unnecessary risks and costs, whereas undertreatment may allow irreversible bowel damage and complications to develop. This narrative review summarises the current evidence on the definition, assessment, treatment, and monitoring of low-risk paediatric CD, highlighting existing knowledge gaps and future research priorities. At present, no consensus definition of low-risk paediatric CD exists, and disease classification relies largely on the absence of recognised high-risk features rather than validated criteria. Similarly, unlike adult practice, no paediatric prognostic model is available to identify children likely to follow a persistently mild disease course. Current assessment requires integration of clinical indices, inflammatory biomarkers, endoscopy, cross-sectional imaging, and evaluation of growth and nutritional status. Dietary treatment (Exclusive Enteral Nutrition and emerging dietary strategies, including the CD Exclusion Diet [CDED] and the Tasty & Healthy [T&H]] remains the commonest induction therapy. Budesonide or antibiotics (azithromycin and metronidazole) represent an appropriate alternative for selected children. CDED and the T&H diet may also represent attractive medium term treatment options, although robust maintenance data are still awaited. Prospective studies are needed to establish a consensus definition, develop paediatric-specific prediction models, optimise risk stratification, and determine the most effective long-term therapeutic and monitoring approaches for the 'low-risk' population.
Chen Ellie E, Cusumano Vivy V
Celiac disease is an immune-mediated enteropathy triggered by dietary gluten. Celiac crisis is a severe manifestation characterized by profuse diarrhea, dehydration, hypotension, and severe metabolic derangements. We describe the case of an elderly patient with a remote childhood diagnosis of celiac disease who presented in celiac crisis. A 79-year-old man with hypertension managed on olmesartan presented with two weeks of severe watery diarrhea, weight loss, and edema that progressed to hypotension, acute kidney injury, and profound electrolyte abnormalities, necessitating multiple hospitalizations. Celiac serologies were markedly elevated, and he subsequently disclosed a childhood diagnosis of celiac disease that he had believed resolved. Duodenal biopsies demonstrated duodenitis with intraepithelial lymphocytosis and villous blunting. His symptoms persisted despite a gluten-free diet, withholding olmesartan, and supportive care but improved rapidly after initiation of budesonide. He was diagnosed with celiac crisis, with a possible contribution from olmesartan-associated enteropathy. Repeat endoscopy eight months later showed histologic remission. Celiac crisis should be considered in any patient presenting with severe diarrhea, dehydration, and metabolic abnormalities, especially when there is evidence of underlying celiac disease. In this patient, concurrent olmesartan use raised the possibility of a superimposed drug-induced enteropathy; although olmesartan was discontinued five days before budesonide was started, its contribution cannot be excluded and remains a confounding factor. Even so, this case highlights the importance of promptly recognizing celiac crisis and suggests a potential role for budesonide in patients whose symptoms persist despite gluten withdrawal and supportive care.
注册免费账户还可查看另外 7181 篇文献
免费注册查看全部文献 →